CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
AlphaTar aims to enhance targeted alpha therapy for metastatic cancer by using ultra-small nanoformulations to deliver radioactive materials directly to tumors. This innovative approach seeks to minimize side effects and improve treatment efficacy, potentially expanding the therapy's application beyond terminal cases.
Targeted alpha therapy, a treatment that relies on targeting pharmaceuticals labeled with ⍺ emitters, has produced complete cures of metastatic cancer patients with refractory diseases in clinical trials.
However, targeted alpha therapy is limited by the release of radioisotopes from the pharmaceuticals.
In ⍺ emissions, the decay products break the chemical bonds by which they are bound to the radiopharmaceutical, and once liberated, they spread all over the body, causing off-target radiopoisoni…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
